Disubstituted 1-aryl-4-aminopiperidine library synthesis using computational drug design and high-throughput batch
Marian C Bryan1, Christopher D Hein, Hua Gao
1Medicinal Chemistry Research Technologies, ‡Molecular Structure and Characterization, and §Pharmacokinetics and Drug Metabolism, Therapeutic Discovery, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States.
ACS Combinatorial Science
|August 10, 2013
Summary
A novel platform integrates computational design and automated synthesis to produce diverse 1-aryl-4-aminopiperidine analogues for drug discovery. This approach accelerates the creation of compound libraries for screening.
Area of Science:
- Medicinal Chemistry
- Drug Discovery
- Chemical Synthesis
Background:
- Drug discovery relies on screening diverse compound libraries.
- Efficient synthesis of analogues is crucial for identifying lead compounds.
- Traditional methods can be time-consuming and resource-intensive.
Purpose of the Study:
- To develop and demonstrate an integrated platform for rapid analogue library production.
- To showcase the benefits of computational library design and modular synthesis.
- To enable medicinal chemists to generate compound libraries efficiently.
Main Methods:
- Utilized computational library design for analogue selection.
- Employed parallel solution-phase synthesis and continuous flow hydrogenation.
- Incorporated automated high-throughput purification and reformatting.
Main Results:
- Successfully produced a 120-member library of 1-aryl-4-aminopiperidine analogues.
- Demonstrated the advantages of combining computational design with automated synthesis.
- Validated the platform's flexibility and modularity.
Conclusions:
- The integrated platform accelerates the production of compound libraries for drug discovery.
- Computational design coupled with automated synthesis offers significant advantages.
- The described technologies are readily adoptable by medicinal chemists.
Related Concept Videos
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...